Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill
This initiative comes amid targets on international students at U.S. universities and growing concerns over the increasing number of J-1 visa denials, which prevent qualified international medical graduates (IMGs)—especially Nigerian-trained physicians—from contributing their expertise to underserved and rural communities across the United States. Nigerian American physicians have played an important role in filling healthcare shortages in the United States and the advancement of our country's healthcare system is dependent on the removal of systemic barriers to their continued service.
"Doctors from Nigeria and across Africa have long served in America's most vulnerable communities—from inner cities to remote rural counties," said Dr. Susan Edionwe. "Fixing the J-1 process and passing H.R. 1201 is essential to ensuring our communities have access to the care they desperately need."
"NPAG encourages policymakers, allies, and the media to recognize the indispensable contribution of Nigerian and African-trained doctors to the American healthcare system—and to take legislative action to protect and expand their role in advancing national health equity," said Dr. Susan Edionwe.
About Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201): H.R. 1201 a bipartisan bill, would reauthorize and expand the Conrad 30 waiver program, which allows J-1 physicians to remain in the U.S. after residency by serving in Health Professional Shortage Areas (HPSAs). The legislation provides states with greater flexibility, increases waiver caps, and reduces processing delays—ensuring medically underserved communities continue receiving essential care.
About NPAG: The Nigerian Physician Advocacy Group is a national coalition of Nigerian American doctors and advocates committed to advancing health equity, shaping inclusive immigration policy, and addressing physician workforce challenges in the United States.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nigerian-medical-advocates-rally-on-capitol-hill-for-j-1-visa-fix-and-immigrant-physician-bill-302476909.html
SOURCE Nigerian Physician Advocacy Group (NPAG)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030. The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector. This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes. The factors driving the market's growth include: Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development. Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare. Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment. Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics. Request a sample copy of the global market for proteomic technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $27.6 billion Market size forecast $57.2 billion Growth rate CAGR of 13.0% from 2025 to 2030 Segments covered Platform, Application, Product Type and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe Market drivers Increasing investments in R&D. Transition towards personalized medicine. Aging population and growing prevalence of chronic diseases. Emerging technologies. Interesting facts: Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation. Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future. Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. Sengenics The report addresses the following questions: What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030. Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine. Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region. Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030. Which region has the largest market share?- North America holds the largest share of the market. Market Leaders include: AGILENT TECHNOLOGIES INC. ARRAYIT CORP. BIO-RAD LABORATORIES INC. BIO-TECHNE BRUKER CREATIVE PROTEOMICS DANAHER CORP. JEOL LTD. MERCK KGAA PROMEGA CORP. REVVITY SHIMADZU CORP. STANDARD BIOTOOLS THERMO FISHER SCIENTIFIC INC. WATERS CORP. Related reports: Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments. Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
Medscape
11 hours ago
- Medscape
GLP-1s Only Opening Act: Experts Unveil Diet-Exercise Guide
The weight loss seen with GLP-1 receptor agonists is only half the story. Long-term success hinges on integrating medication with individualized nutrition and physical activity counseling, a trio of experts remind clinicians in a new paper. GLP-1 medications and dual receptor agonist medications are 'very effective in terms of weight loss, achieving about 20% weight loss or more,' JoAnn Manson, MD, MPH, professor of medicine, Harvard Medical School and Brigham and Women's Hospital, both in Boston, told Medscape Medical News . However, the loss of muscle mass and lean body mass is also 'quite common, sometimes accounting for 25% or more of the total weight loss.' Lifestyle factors are 'crucial' to optimize outcomes for patients on GLP-1 medications, Manson said. She and her coauthors offered advice on integrating diet and physical activity and managing potential side effects in patients with obesity starting a GLP-1 medication in a brief two-page 'Clinical Insights' article in JAMA Internal Medicine. There is also companion 'Patient Page.' Monitor Weight Loss Clinicians should track weight monthly during GLP-1 dose escalation and at least quarterly thereafter, intervening if patients lose too little or too much weight, the authors advised. For those with < 5% weight loss after 12-16 weeks, options include continuing standard dose escalation and documenting progress, given that standard titration periods (at least 17 weeks) may not work for all individuals; checking for missed doses and adjust dose titration as needed to maximize adherence; or switching to an alternative GLP-1 drug if the maximum tolerated dose is not effective, they said. It's also important to monitor for excessive weight loss, the authors said. Indications that weight loss may be excessive or harming overall health include a BMI < 18.5, anorexia (consuming < 800 calories/d), or very low protein intake. In a patient with excessive weight loss, it's important to rule out secondary causes such as eating or endocrine disorders or malignant tumors, assess for correlated harms including nutrient deficiencies and hormonal imbalances, assess psychological function with referrals to specialists as needed, and consider dose reduction or stopping the medication temporarily, the author advised. Assess Diet, Manage Nutrient Intake If available, patients should see a registered dietitian initially, with follow-up visits every 2-3 months during dose escalation. If this is not feasible, clinicians can administer the Rapid Eating Assessment for Participants-Shortened, a brief nutritional assessment tool. The authors emphasized that nutrient quality is more important than rigid calorie counting. However, patients may also benefit from periodic tracking of their food and fluid intake through smartphone applications, manual food logs or taking photos of their food to help guide dietary adjustments. For patients comfortable with tracking their calories, target calorie ranges should be individualized based on weight goals and activity level. To minimize muscle loss, patients should be advised to maintain adequate protein intake of 60-75 g/d (1.0-1.5 g/kg; > 1.5 g/kg for older or post-bariatric surgery patients) and engage in structured physical activity (aerobic and strength training). To maintain energy balance, smaller, nutrient-dense meals rather than calorie restriction is advised. Whole grains for satiety and sustained energy and healthy fats to support fat-soluble vitamin absorption and reduce cholestasis are recommended. Manson noted that 'gastrointestinal symptoms — such as nausea, constipation, and reflux — can limit the use of these medications, lead to drug discontinuation, and subsequently results in weight regain.' To help ward off constipation, patients should be advised to increase fiber intake and take in more than 2-3 L of fluid a day and use over-the-counter laxatives if needed. For nausea, they should avoid fried foods and carbonated drinks. For reflux, eating smaller portions, not lying down for 2-3 hours after meals and limiting high-fat and irritating spices may help. Because appetite suppression induced by GLP-1 medications can unmask hidden micronutrient deficiencies, clinicians could consider assessment of vitamin D, iron, B-vitamins, and other micronutrients and add a multivitamin when intake is chronically low, the authors said. Physical Activity: Start Slow and Add-On The authors recommend a three-step approach to counseling patients on physical activity. First, introduce regular movement gradually and work up to 150 minutes of moderate (or 75 min of vigorous) activity weekly. Second, incorporate resistance training, aiming for 60-90 min/wk. Third, maintain 30-60 minutes per day of aerobic exercise combined with resistance training two to three times per week for optimal long-term weight and metabolic outcomes. Balance and mobility training for older adults can be especially helpful, the author said. Clinicians may also consider assessing muscle strength and function, such as the grip strength or 6-minute walk test, the authors said. Weight Regain Patients who discontinue GLP-1 therapy may regain weight and this should be discussed with patients at the start of treatment, the authors said. Specifically, in randomized controlled trials, weight rebound of roughly 7%-12% has been observed within 1 year of stopping GLP-1 therapy and that lifestyle habits put in place early will be the main defense if dose reductions or discontinuation are attempted. The authors noted that all patients will reach a weight-loss plateau, but weight maintenance protocols for GLP-1 drugs have yet to be established. 'Clinicians should base treatment decisions on the premise that obesity is a chronic condition typically requiring long-term management, similar to hypertension,' they advised. When a decision to taper the medication is made, options include reducing the dose or frequency of injections or tapering off treatment completely with progressively less monitoring (weekly to biweekly, followed by monthly, then quarterly) over at least 20 weeks. 'Clinicians should continue to assess weight, metabolic health, diet and activity levels, appetite, sleep patterns, mood changes, and muscle strength. Medication reinitiation or dose increase should be considered if weight regain exceeds 5%,' they advised. Manson told Medscape Medical News she hopes this information will be a 'good resource that will result in better care for patients on GLP-1 medications and better outcomes.'
Yahoo
13 hours ago
- Yahoo
Weight-loss jabs could minimise the symptoms of asthma
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. READ MORE: Brits issued drink warning at popular Mediterranean holiday spot READ MORE: Gran banned from Asda after being accused of swapping yellow stickers 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
